On Demand 2019 Monday General Sessions

This collection covers general sessions from Monday's program. The sessions listed below are included in this package:

  • Allergists Can Offer More Than Just Skin Testing
  • Urticaria: Are You Itching to Learn More
  • Climate Change and Natural Disasters: The Central Role of Allergists
  • New Horizons in Chronic Rhinosinusitis
  • Managing the Patient with Recurrent Infections

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 7.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Of the AMA PRA Category 1 Credits™ listed above, the ABAI has designated a maximum of 3 credits as meeting the requirements for MOC Part II Self-Assessment.

Target Audience

Medical professionals who treat patients with allergic and/or immunological conditions:

  • Practicing allergist/immunologists
  • Allergy/immunology Fellows-in-Training
  • Physician assistants
  • Nurses and advanced practice nurses
  • Allied health professionals
  • Primary care physicians
  • Other medical professionals

Learning Objectives

Upon completion of this session, participants should be able to:

  • Understand how the FDA approval process determines availability of treatment options
  • Address psychosocial aspects of living with allergic conditions with patients during clinical encounters
  • Maintain relevance within our specialty through proactive approaches to patient care and education
  • Focus on quality measures to help guide optimal patient care
  • Define the criteria for chronic and inducible urticaria. Formulate an appropriate diagnostic workup for symptoms suggestive of CIU and inducible urticaria.
  • Recognize the various patterns of urticaria and their therapeutic implications, taking into account the potential differential diagnosis.
  • Identify components of step-wise management of urticaria following national and international guidelines.
  • Be able to discuss various treatment options along with risks versus benefits, including approved biologic therapy, taking into account patient quality-of-life issues.
  • Discuss possible roles for allergists in addressing air quality disasters.
  • Anticipate medication challenges facing patients during poor air quality.
  • Be able to work with public health to develop health care plans for at-risk populations.
  • Recognize CRS as a clinical issue and develop an improved knowledge of the etiology and pathogenesis.
  • Be able to develop a management plan for a patient with CRS based on new medical and surgical management options.
  • Appreciate the involvement of Type 2 inflammation in CRS and the role biologics may play in management.
  • Identify factors that affect long-term outcomes in children with PIDD.
  • Identify factors that affect long-term outcomes in adults with PIDD.
  • Identify and manage two frequent comorbidities: autoimmune cytopenias and malignancies.
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma & Immunology (ACAAI) policy, the College must identify and resolve conflicts of interest for all individuals responsible for the development, management, presentation, and/ or evaluation relevant to a CME activity. Disclosed information is reviewed in advance in order to manage and resolve any potential conflicts of interest. Disclosure in no way implies that the information presented is biased or of lesser quality; it is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations.

Specific disclosure information for the 2019 Annual Meeting is available online and via the meeting app

Course summary
Available credit: 
  • 7.75 AMA PRA Category 1 Credit™
  • 7.75 Attendance
  • 3.00 MOC
Course opens: 
12/01/2019
Course expires: 
11/30/2022
Rating: 
0

Mark M. Ballow, MD, FACAAI

Jonathan A. Bernstein, MD, FACAAI

William K. Dolen, MD, FACAAI

Mary B. Fasano, MD, MSPH, FACAAI

Thomas A. Fleisher, MD, FACAAI

Luz S. Fonacier, MD, FACAAI

Sandra M. Gawchik, DO, FACAAI

Maya Gharfeh, MD, MPH

Alan B. Goldsobel, MD, FACAAI

Joseph Han, MD

Allen Kaplan, MD, FACAAI

Bryan L. Martin, DO, FACAAI

Marcus Maurer, MD

J. Allen Meadows, MD, FACAAI

S. Shahzad Mustafa, MD, FACAAI

Michael R. Nelson, MD, PhD, FACAAI

David B. Peden, MD, FACAAI

Anju T. Peters, MD

Nicholas Rider, DO

Hemant Sharma, MD

Meagan W. Shepherd, MD, FACAAI

Puneet Shroff, MD FACAAI

Jonathan S. Tam, MD, FACAAI

David R. Weldon, MD, FACAAI

Available Credit

  • 7.75 AMA PRA Category 1 Credit™
  • 7.75 Attendance
  • 3.00 MOC

Accreditation Period

Course opens: 
12/01/2019
Course expires: 
11/30/2022
Please login or create an account to take this course.